

American
National
Standard

ANSI/AAMI
ST91:2015

Flexible and semi-rigid
endoscope processing in
health care facilities

Objectives and uses of AAMI standards and recommended practices

It is most important that the objectives and potential uses of an AAMI product standard or recommended practice are clearly understood. The objectives of AAMI's technical development program derive from AAMI's overall mission: the advancement of medical instrumentation. Essential to such advancement are (1) a continued increase in the safe and effective application of current technologies to patient care, and (2) the encouragement of new technologies. It is AAMI's view that standards and recommended practices can contribute significantly to the advancement of medical instrumentation, provided that they are drafted with attention to these objectives and provided that arbitrary and restrictive uses are avoided.

A voluntary *standard* for a *medical device* recommends to the manufacturer the information that should be provided with or on the product, basic safety and performance criteria that should be considered in qualifying the device for clinical use, and the measurement techniques that can be used to determine whether the device conforms with the safety and performance criteria and/or to compare the performance characteristics of different products. Some standards emphasize the information that should be provided with the device, including performance characteristics, instructions for use, warnings and precautions, and other data considered important in ensuring the safe and effective use of the device in the clinical environment. Recommending the disclosure of performance characteristics often necessitates the development of specialized test methods to facilitate uniformity in reporting; reaching consensus on these tests can represent a considerable part of committee work. When a drafting committee determines that clinical concerns warrant the establishment of *minimum* safety and performance criteria, referee tests must be provided and the reasons for establishing the criteria must be documented in the rationale.

A *recommended practice* provides guidelines for the use, care, and/or processing of a medical device or system. A recommended practice does not address device performance *per se*, but rather procedures and practices that will help ensure that a device is used safely and effectively and that its performance will be maintained.

Although a device standard is primarily directed to the manufacturer, it may also be of value to the potential purchaser or user of the device as a frame of reference for device evaluation. Similarly, even though a recommended practice is usually oriented towards healthcare professionals, it may be useful to the manufacturer in better understanding the environment in which a medical device will be used. Also, some recommended practices, while not addressing device performance criteria, provide guidelines to industrial personnel on such subjects as sterilization processing, method of collecting data to establish safety and efficacy, human engineering, and other processing or evaluation techniques; such guidelines may be useful to health care professionals in understanding industrial practices.

In determining whether an AAMI standard or recommended practice is relevant to the specific needs of a potential user of the document, several important concepts must be recognized:

All AAMI standards and recommended practices are *voluntary* (i.e., of course, they are adopted by government regulatory or procurement authorities). The application of a standard or recommended practice is solely within the discretion and professional judgment of the user of the document.

Each AAMI standard or recommended practice reflects the collective expertise of a committee of health care professionals and industrial representatives, whose work has been reviewed nationally (and sometimes internationally). As such, the consensus recommendations embodied in a standard or recommended practice are intended to respond to clinical needs and, ultimately, to help ensure patient safety. A standard or recommended practice is limited, however, in the sense that it responds generally to perceived risks and conditions that may not always be relevant to specific situations. A standard or recommended practice is an important *reference* in responsible decision-making, but it should never *replace* responsible decision-making.

Despite periodic review and revision (at least once every five years), a standard or recommended practice is necessarily a static document applied to a dynamic technology. Therefore, a standards user must carefully review the reasons why the document was initially developed and the specific rationale for each of its provisions. This review will reveal whether the document remains relevant to the specific needs of the user.

Particular care should be taken in applying a product standard to existing devices and equipment, and in applying a recommended practice to current procedures and practices. While observed or potential risks with existing equipment typically form the basis for the safety and performance criteria defined in a standard, professional judgment must be used in applying these criteria to existing equipment. No single source of information will serve to identify a particular product as "unsafe". A voluntary standard can be used as one resource, but the ultimate decision as to product safety and efficacy must take into account the specifics of its utilization and, of course, cost-benefit considerations. Similarly, a recommended practice should be analyzed in the context of the specific needs and resources of the individual institution or firm. Again, the rationale accompanying each AAMI standard and recommended practice is an excellent guide to the reasoning and data underlying its provision.

In summary, a standard or recommended practice is truly useful only when it is used in conjunction with other sources of information and policy guidance and in the context of professional experience and judgment.

INTERPRETATIONS OF AAMI STANDARDS AND RECOMMENDED PRACTICES

Requests for interpretations of AAMI standards and recommended practices must be made in writing, to the AAMI Vice President, Standards Policy and Programs. An official interpretation must be approved by letter ballot of the originating committee and subsequently reviewed and approved by the AAMI Standards Board. The interpretation will become official and representation of the Association only upon exhaustion of any appeals and upon publication of notice of interpretation in the "Standards Monitor" section of the *AAMI News*. The Association for the Advancement of Medical Instrumentation disclaims responsibility for any characterization or explanation of a standard or recommended practice which has not been developed and communicated in accordance with this procedure and which is not published, by appropriate notice, as an *official interpretation* in the *AAMI News*.

Flexible and semi-rigid endoscope processing in health care facilities

Approved 30 March 2015 by
Association for the Advancement of Medical Instrumentation

Approved 8 April 2015 by
American National Standards Institute Inc.

Abstract. Provides guidelines for precleaning, leak-testing, cleaning, packaging (where indicated), storage, high-level disinfecting, and/or sterilizing of flexible gastrointestinal (GI) endoscopes, flexible bronchoscopes, surgical flexible endoscopes (e.g., flexible ureteroscopes), and semi-rigid operative endoscopes (e.g., choledochoscopes) in health care facilities. These guidelines are intended to provide comprehensive information and direction for health care personnel in the processing of these devices and accessories.

Keywords: flexible endoscopes, high-level disinfection, semi-rigid endoscopes, sterilization

AAMI Standard

This Association for the Advancement of Medical Instrumentation (AAMI) standard implies a consensus of those substantially concerned with its scope and provisions. The existence of an AAMI standard does not in any respect preclude anyone, whether they have approved the standard or not, from manufacturing, marketing, purchasing, or using products, processes, or procedures not conforming to the standard. AAMI standards are subject to periodic review, and users are cautioned to obtain the latest editions.

CAUTION NOTICE: This AAMI standard may be revised or withdrawn at any time. AAMI procedures require that action be taken to reaffirm, revise, or withdraw this standard no later than five years from the date of publication. Interested parties may obtain current information on all AAMI standards by calling or writing AAMI.

All AAMI standards, recommended practices, technical information reports, and other types of technical documents developed by AAMI are *voluntary*, and their application is solely within the discretion and professional judgment of the user of the document. Occasionally, voluntary technical documents are adopted by government regulatory agencies or procurement authorities, in which case the adopting agency is responsible for enforcement of its rules and regulations.

Published by

Association for the Advancement of Medical Instrumentation
4301 N. Fairfax Dr., Ste. 301
Arlington, VA 22203-1633

© 2015 by the Association for the Advancement of Medical Instrumentation

All Rights Reserved

Publication, reproduction, photocopying, storage, or transmission, electronically or otherwise, of all or any part of this document without the prior written permission of the Association for the Advancement of Medical Instrumentation is strictly prohibited by law. It is illegal under federal law (17 U.S.C. § 101, *et seq.*) to make copies of all or any part of this document (whether internally or externally) without the prior written permission of the Association for the Advancement of Medical Instrumentation. Violators risk legal action, including civil and criminal penalties, and damages of \$100,000 per offense. For permission regarding the use of all or any part of this document, contact AAMI at 4301 N. Fairfax Dr., Suite 301, Arlington, VA 22203-1633. Phone: (703) 525-4890; Fax: (703) 525-1067.

Printed in the United States of America

ISBN 1-57020-585-X

Contents

Page

Glossary of equivalent standards.....	vi
Committee representation.....	vii
Foreword.....	ix
Introduction.....	1
1 Scope.....	3
1.1 Inclusions.....	3
1.2 Exclusions.....	3
2 Definitions and abbreviations.....	
3 Design of endoscope processing area.....	8
3.1 General considerations.....	8
3.2 Work flow.....	8
3.2.1 General considerations.....	8
3.2.2 Physical separation.....	8
3.2.3 Traffic control.....	9
3.3 Physical facilities.....	9
3.3.1 Space requirements.....	9
3.3.2 Sinks and accessories.....	10
3.3.3 Electrical systems.....	10
3.3.4 Floors and walls.....	10
3.3.5 Ceilings.....	11
3.3.6 Doors.....	11
3.3.7 Temperature, relative humidity, and ventilation.....	11
3.3.8 Lighting.....	12
3.3.9 Hand hygiene facilities.....	13
3.3.10 Emergency eyewash/shower equipment.....	13
3.3.11 Environmental cleaning.....	14
4 Personnel.....	14
4.1 General considerations.....	14
4.2 Policies and procedures.....	14
4.3 Education, training, and competency verification.....	15
4.4 Standard precautions.....	16
4.5 Hand hygiene.....	17
4.6 Attire.....	17
4.6.1 General considerations.....	17
4.6.2 Personal protective equipment.....	17
4.7 Immunizations.....	18
5 Cleaning and high-level disinfection.....	19
5.1 General considerations.....	19
5.2 Precleaning at the point of use.....	19
5.3 Transporting used endoscopes.....	19
5.4 Leak testing.....	20
5.4.1 General considerations.....	20
5.4.2 Manual (dry) leak testing.....	20

5.4.3	Mechanical (wet) leak testing	20
5.4.4	Mechanical (dry) leak testing	21
5.4.5	Mechanical leak testing using an AER	21
5.4.6	Leak test failures	22
5.5	Manual cleaning.....	22
5.6	Manual rinsing	23
5.7	High-level disinfection and liquid chemical sterilization.....	23
5.7.1	General considerations.....	23
5.7.2	High-level disinfection.....	25
5.7.3	Liquid chemical sterilants/liquid chemical sterilization.....	24
5.7.4	Manual liquid chemical sterilization/high-level disinfection	24
6	Automated endoscope reprocessors	26
7	Sterile endoscope sheaths used as protective microbial barriers	28
8	Terminal sterilization by gaseous chemical sterilization processes.....	28
8.1	General considerations.....	28
8.2	Packaging for terminal sterilization	29
8.2.1	General considerations.....	29
8.2.2	Sterilization pouches	29
8.2.3	Sterilization wraps	29
8.2.4	Rigid sterilization containment systems.....	29
8.3	Ethylene oxide gas (EO) sterilization	29
8.4	Hydrogen peroxide gas sterilization.....	30
8.5	Ozone sterilization	31
9	Processing of endoscope accessories.....	31
10	Storage of reprocessed endoscopes	32
10.1	General Considerations	32
10.2	Storage of high-level disinfected endoscopes.....	33
10.3	Storage of sterilized endoscopes.....	33
10.4	Hang time for high-level disinfected endoscopes.....	33
10.4.1	General considerations	33
10.4.2	Existing guidelines.....	33
10.4.3	Risk assessment	34
11	Transport of high-level disinfected endoscopes	35
12	Quality Control	35
12.1	General considerations	35
12.2	Product identification and traceability.....	37
12.3	Documentation and record-keeping.....	37
12.3.1	Documentation	37
12.3.2	Expiration dating.....	38
12.4	Verification and monitoring of the cleaning process.....	38
12.4.1	General Considerations	38
12.4.2	Cleaning verification.....	39
12.4.3	Cleaning verification tests for users	39
12.4.4	Testing cleaning efficacy	40
12.5	Monitoring processes that use liquid chemical sterilization/high-level disinfection.....	40
12.5.1	Manual processes	40

12.5.2	Automated processes.....	42
12.6	Monitoring gaseous chemical sterilization processes	44
12.6.1	Use of physical monitors	44
12.6.2	Gaseous chemical sterilizer malfunction	44
12.7	Chemical indicators.....	45
12.7.1	General considerations.....	45
12.7.2	Using chemical indicators.....	45
12.7.3	Nonresponsive or inconclusive chemical indicators.....	45
12.8	Biological indicators	46
12.8.1	General considerations.....	46
12.8.2	Using biological indicators and process challenge devices	46
12.8.3	Frequency of use of BIs and PCDs	46
12.9	Sterilizer testing	46
12.9.1	General considerations.....	46
12.9.2	Qualification test procedure with BIs	47
12.9.3	Qualification testing acceptance criteria	47
12.9.4	Routine test procedure with BIs.....	47
12.9.5	Routine testing acceptance criteria.....	47
12.9.6	Positive BI results.....	47
12.9.7	Microbiological testing	48
12.9.8	Product release	48
12.10	Product recalls.....	48
12.10.1	General considerations.....	48
12.10.2	Recall procedure	49
12.10.3	Recall order	49
12.10.4	Recall summary report	49
12.10.5	Outbreak report	49
12.11	Quality process improvement	49
12.11.1	General considerations.....	49
12.11.2	Risk analysis.....	50
12.11.3	Decontamination.....	51
12.11.4	Liquid chemical sterilization, high-level disinfection, and gaseous chemical sterilization	51
12.11.5	Functional analysis for product and process improvement.....	52
	Bibliography	54

Tables

1	IES-recommended illuminance levels for work environments.....	22
2	Endoscope storage risk assessment checklist.....	44

Glossary of equivalent standards

International Standards adopted in the United States may include normative references to other International Standards. AAMI maintains a current list of each International Standard that has been adopted by AAMI (and ANSI). Available on the AAMI website at the address below, this list gives the corresponding U.S. designation and level of equivalency to the International Standard.

www.aami.org/standards/glossary.pdf

Currently in preview, click buy full version

Committee representation

Association for the Advancement of Medical Instrumentation

Endoscope Reprocessing Working Group

This standard was developed by the AAMI Endoscope Reprocessing Working Group under the auspices of the AAMI Sterilization Standards Committee. Approval of the standard does not necessarily mean that all working group members voted for its approval. At the time this standard was published, the **AAMI Endoscope Reprocessing Working Group** had the following members:

- Chairs:* Nancy Chobin, RN CSPDM, St Barnabas Healthcare System
Mary Ann Drosnock, MS, Olympus America Inc
- Members:* Jahan Azizi, CBET, University of Michigan Health System
James Weldon Baker, AmeriWater
Damien Berg, Medical Center of the Rockies
Holger Biering, PhD, Holger Biering
Harriet Chan-Myers, Johnson & Johnson
James W. Collins, RN, Cleveland Clinic Foundation
Linda Condon, Johns Hopkins Hospital
Jacqueline Daley, Sinai Hospital of Baltimore
Robert Dumont, Case Medical Inc
Jon Fish, Prezio Health
Sarah Friedberg, Stryker Instruments Division
Shelley Green, WuXi AppTec Inc
Garland Grisby, Kaiser Permanente (US)
Barbara Ann Harmer, RN BSN MHA
Shanil Haugen, FDA/CDRH
Emily A. Hildebrand, Phoenix VA Health Care System
Rachel Hill, CareFusion
Nupur Jain, Intuitive Surgical Inc
Susan G. Klacik, CCSMC FCS ACE, IAHCSPM
Stephen M. Kovach, Healthmark Industries Company Inc
Carole Kubiak, BSN RN CNOR, Brigham & Womens Hospital
Colleen Patricia Landers, RN, Timmins & District Hospital
Steve Maley, Crouse Hospital
Albert E. May, Andersen Products Inc
Gerald E. McDonnell, PhD, Steris Corporation
Terry Mistalski, Medivators Inc
Emily Mitzel, MS, Nelson Laboratories Inc
Frank Myers, USPHS Indian Health Service
Phillip Nosel, Microtest Laboratories Inc
Gerry A. O'Dell, MS, Gerry O'Dell Consulting
Janet M. Prus, St. Joseph Healthcare
Wayne Jerome Rogers, Wayne J Rogers Consulting
Cheron F. Rojas, Childrens Hospital Central California
Janis Sannier, Medtronic Inc WHQ Campus
Rose E. Seavey, RN MBA CNOR CRCST, Seavey Healthcare Consulting, LLC
Frank Smith, RN CNOR CRCST, Department of Veteran Affairs
Donald Socha, Jr., Getinge USA
Cynthia Spry, RN, Spry Consulting
Christopher Strafaci, Vision Sciences Inc
Karen Swanson, Connecticut Childrens Medical Center
Lynne A. Thomas, Integrated Medical Systems
Sharon Van Wicklin, MSN RN CNOR/CRNFA, Association of Perioperative Registered Nurses
Don T. Williams, CRCST CIS CHL, Overlake Hospital Medical Center
Martha L. Young, Martha L Young, LLC
- Alternates:* David E. Barlow, PhD, Olympus America Inc
Ralph J. Basile, MBA, Healthmark Industries Company Inc
Marcia Benedict, BS MI RAC MT ASCP, Steris Corporation
Denise Carey, Medtronic Inc WHQ Campus
Ramona Conner, RN MSN CNOR, Association of Perioperative Registered Nurses
Sylvie Dufresne, PhD, TSO3 Inc

Christian Escobar, Vision Sciences Inc
Tania Lupu, Case Medical Inc
Elaine S. Mayhall, PhD, FDA/CDRH
Kanwarjit Singh, Johnson & Johnson
Grace A. Thornhill, PhD, 3M Healthcare
Brian Wallace, Intuitive Surgical Inc
Ann Wheeler, Getinge USA

NOTE—Participation by federal agency representatives in the development of this recommended practice does not constitute endorsement by the federal government or any of its agencies.

At the time this document was published, the **AAMI Sterilization Standards Committee** had the following members:

Co-chairs: Victoria M. Hitchins, PhD, FDA/CDRH

Michael H. Scholla, Dupont Protection Technologies

Members: Christopher Anderson, Boston Scientific Corporation

Trabue D. Bryans, BryKor LLC

Nancy Chobin, RN CSPDM, St Barnabas Healthcare System

Charles Cogdill, Covidien

Ramona Conner, RN MSN CNOR, Association of Perioperative Registered Nurses

Jacqueline Daley, Sinai Hospital of Baltimore

Kimbrell Darnell, CR Bard

Lisa Foster, Medpoint LLC

Joel R. Gorski, PhD, NAMSA

Joyce M. Hansen, Johnson & Johnson

Douglas F. Harbrecht, Sterility Assurance LLC

Deborah A. Havlik, Hospira Worldwide Inc

Susan G. Klacik, CCSMC FCS ACE, IAHCSSM

Byron J. Lambert, PhD, Abbott Laboratories

Colleen Patricia Landers, RN, Timmins & District Hospital

Reynaldo Lopez, Cardinal Health (MP&S)

Jeff Martin, Alcon Laboratories Inc

Patrick J. McCormick, PhD, Bausch & Lomb Inc

Gerald E. McDonnell, PhD, Steris Corporation

Janet M. Prust, 3M Healthcare

Nancy Rakiewicz, Moog Medical Devices

Mark Seybold, Baxter Healthcare Corporation

Andrew Sharavara, PhD, Propper Manufacturing Co Inc

Mark N. Smith, Getinge USA

James Sidney Wiggs, BSN CRCST, Legacy Health System

Martell Kress Winters, BS CM, Nelson Laboratories Inc

William E. Young

Alternates: William T. Young, Sterigenics International

Lloyd Brown, Covidien

Peter A. Burke, PhD, Steris Corporation

Dave Dion, Cardinal Health (MP&S)

Gordon M. Fly, WuXi AppTec Inc

Thomas J. Frazar, Johnson & Johnson

Martha M. Kaldas, Sterigenics International

Jim Kaiser, Bausch & Lomb Inc

Natalie Lind, IAHCSSM

Ralph Makinen, Boston Scientific Corporation

May S. Mayo, CR Bard

David Ford McGoldrick, BS, Abbott Laboratories

Jerry R. Nelson, PhD, Nelson Laboratories Inc

Patrick Polito, Moog Medical Devices

Karen Polkinghorne, Dupont Protection Technologies

Shaundrea L. Rechsteiner, NAMSA

Mike Sadowski, Baxter Healthcare Corporation

Craig A. Wallace, 3M Healthcare

NOTE—Participation by federal agency representatives in the development of this recommended practice does not constitute endorsement by the federal government or any of its agencies.

Foreword

This standard was developed by the AAMI Endoscope Reprocessing Working Group under the auspices of the AAMI Sterilization Standards Committee. The objective of this standard is to provide guidelines for precleaning, leak-testing, cleaning, packaging (where indicated), storage, high-level disinfecting, and/or sterilizing of flexible gastrointestinal (GI) endoscopes, flexible bronchoscopes, surgical flexible endoscopes (e.g., flexible ureteroscopes), and semi-rigid operative endoscopes (e.g., choledochoscopes) in health care facilities. These guidelines are intended to provide comprehensive information and direction for health care personnel in the processing of these devices and accessories.

Initially this document was proposed as a technical information report that would synthesize existing guidance in the area of endoscope processing. As the draft was developed, the working group identified a need in the field for more extensive guidance, and proposed revising the document to be an American National Standard.

As used within the context of this document, “shall” indicates requirements strictly to be followed in order to conform to the standard; “should” indicates that among several possibilities one is recommended as particularly suitable, without mentioning or excluding others, or that a certain course of action is preferred but not necessarily required, or that (in the negative form) a certain possibility or course of action should be avoided but is not prohibited; “may” is used to indicate that a course of action is permissible within the limits of the standard; and “can” is used as a statement of possibility and capability. “Must” is used only to describe “unavoidable” situations, including those mandated by government regulation.

This standard should be considered flexible and dynamic. As technology advances and as new data are brought forward, the standard will be reviewed and, if necessary, revised.

Suggestions for improving this recommended practice are invited. Comments and suggested revisions should be sent to Technical Programs, AAMI, 4301 N. Fairfax Drive, Suite 301, Arlington, VA 22203-1633.

Flexible and semi-rigid endoscope processing in health care facilities

Introduction

Flexible and semi-rigid endoscopes are used in various body cavities for diagnostic and therapeutic procedures. In United States, at least 11 million gastrointestinal endoscopies are performed each year and the number of procedures is increasing (Cullen et al, 2009; SGNA, 2012). A risk of all endoscopy procedures is the introduction of pathogens or cross-contamination between patients. Failure to clean, disinfect, or sterilize equipment carries not only risk associated with breach of host barriers but also risk for person-to-person transmission of pathogens and transmission of environmental pathogens (e.g., *Pseudomonas aeruginosa*). Further consequences of inadequate device processing can include device damage, inefficient use of the device, and toxic reactions in patients.

Endoscopic transmission of infection

Even though gastrointestinal endoscopes represent a valuable diagnostic and therapeutic tool in modern medicine, more health care acquired infections (HAIs) have been linked with the use of contaminated endoscopes than to any other medical device and have been listed in the top ten technology hazards for patients for several years in a row (ECRI). The estimated patient risk, cited by the Centers for Disease Control (CDC) and other organizations, of infection associated with a flexible endoscopy has historically been considered to be rare at 1 in 1.8 million procedures. This estimate of patient risk of infection is not consistent with multiple, more recently published reports of lapses and tens of thousands of patient exposures both in the United States and other countries. In addition, there are other reports of patient exposures to contaminated endoscopes in the media and other public databases that have not been published in peer reviewed literature (Kimmery 1993, Rutala et al, 2007; ASGE, 2011, SGNA, 2012).

When the CDC Division of Healthcare Quality Promotion (formerly the Hospital Infection Program) reviewed its log of investigations between 1980 and 2002, no outbreaks of infection associated with GI endoscopy were found. Since 1990, health care facilities and manufacturers have been required to report to the FDA MAUDE (Manufacturer and User-Facility Device Experience) database any information that reasonably suggests that a device (such as an endoscope, accessory, or automated endoscope washer-disinfector) has caused or contributed to a death, injury, or serious illness of a patient. Review of this open access, non-peer-reviewed database from 1990 to 2002 revealed seven possible occurrences of pathogen transmission during GI endoscopy. Since 2002, the MAUDE database contains multiple references to infections suspected to have occurred after lapses in processing.

Currently, there are no well-designed, published, prospective studies on the incidence of pathogen transmission during GI endoscopy. Estimates of pathogen transmission based on retrospective case reports conclude the current risk estimate may underestimate the true incidence of infection. (Seonae-Vazquez 2006, Holodny, 2012). Citing the 2008 CDC risk estimate may have led health care facilities not to inform, adequately screen for all potential disease transmitting organisms, or treat patients (Dirlam-Langley et al., 2013).

In some reports where patients have been exposed, they were not tested for all pathogenic organisms but only HIV or Hepatitis B viruses, despite documented outbreaks of non-viral pathogens. Recent reports support the conclusion that current risks are outdated and inaccurate (Ofstead et al., 2013; Dirlam-Langley et al., 2013). Audits of facilities conducting GI procedures have found widespread lapses in infection control, including endoscope processing and in some cases endoscopes were virtually never processed in accordance with guidelines (Dirlam-Langley et al., 2013). The true implications of inadequate processing are unknown because no epidemiologic studies have determined the risk of infections or other patient complications including residual chemical toxicity and device damage effect on patient outcomes (Leffler et al., 2010).

Multiple peer-reviewed publications in several countries including the United States have documented breaches in processing that have led to patient exposure to improperly reprocessed flexible and semi-rigid endoscopes and have caused serious infections (Sanderson, 2010; Gonzalez-Candelas et al., 2010; Carbonne et al., 2010; Aumeran et al., 2010; Holodny, 2012; CDC 2014). In nearly all of these cases, failure to comply with manufacturer's written instructions for use (IFU) or established guidelines or malfunctioning equipment that was undetected has led to numerous outbreaks of infection due to improperly processed flexible and semi-rigid endoscopes.

A northeastern Illinois outbreak in 2013 of infections with New Delhi metallo- β -lactamase (NDM) producing Carbapenem-resistant Enterobacteriaceae (CRE) was linked with contaminated endoscopes used to perform endoscopic retrograde cholangiopancreatography (ERCP). A total of 44 patients were identified as infected (Rutala 2014). Further outbreaks were similarly linked to ERCP scopes in Pittsburgh (McCool et al., 2012) and Seattle (Aleccia 2015).

Effects of endoscopy-related infection outbreaks and other adverse patient reactions may include:

- microorganisms may be spread from patient to patient by contaminated or improperly processed flexible and semi-rigid endoscopes or malfunctioning equipment (exogenous infections).
- microorganisms may spread from the GI tract through the bloodstream during an endoscopy procedure to susceptible organs, or may spread to adjacent tissues that are breached as a result of the endoscopic procedure (endogenous infections).
- microorganisms may be transmitted from patients to endoscopy personnel and/or from endoscopy personnel to patients.
- chemical substances can remain on devices from various chemicals used during the procedure or processing that can cause toxic reactions in subsequent patients.
- devices may be damaged or rendered difficult to use due to mishandling or inadequate processing.

Minimizing these risks begins with the correct handling procedures in preparation for processing, to include pre-cleaning steps at the point of use (e.g., bedside procedures), disassembly of parts, and safe transport. Cleaning according to the specific manufacturer's written IFU is then required to ensure that patient soil and other materials are removed prior to the antimicrobial processes of high-level disinfection or sterilization. Cleaning is a multi-step process and is critical not only to ensure that subsequent processing steps can be effective but also to remove any potential toxic chemicals or other materials that can lead to adverse patient reactions. Cleaning is followed by disinfection or sterilization to reduce or completely remove microbial contamination. At a minimum, it is recommended that devices are subjected to high-level disinfection after each use. When possible and practical, flexible and semi-rigid endoscopes should be sterilized due to the greater margin of safety built into sterilization. High-level disinfection is a multi-step process and is expected to be able to inactivate most pathogenic bacteria, viruses, and fungi but may not reliably inactivate certain types of microorganisms including bacterial spores. When these devices are used in sterile tissue procedures, sterilization is recommended (CDC 2008).

1 Scope

This standard provides guidelines for precleaning, leak-testing, cleaning, packaging (where indicated), storage, high-level disinfecting, and/or sterilizing of flexible gastrointestinal (GI) endoscopes; flexible bronchoscopes; flexible ear, nose, and throat endoscopes; surgical flexible endoscopes (e.g., flexible ureteroscopes); and semi-rigid operative endoscopes (e.g., choledochoscopes) in health care facilities. These guidelines are intended to provide comprehensive information and direction for health care personnel in the processing of these devices and accessories.

NOTE—For purposes of this standard, “health care facilities” means endoscopy centers, hospitals, nursing homes, extended-care facilities, free-standing surgical centers, ambulatory health centers (clinics), medical offices, and all other areas where flexible and semi-rigid endoscopes are processed.

1.1 Inclusions

This document specifically addresses

- a) functional and physical design criteria for endoscope processing areas;
- b) education, training, competency verification, and other personnel considerations;
- c) processing recommendations;
- d) installation, care, and maintenance of automated processing equipment;
- e) quality control; and
- f) quality process improvement.

Definitions of terms and a bibliography are also provided in this standard.

1.2 Exclusions

This standard does not cover

- a) The processing of rigid endoscopes (e.g., arthroscopes, laparoscopes), transesophageal echocardiogram probes (TEE), or vaginal probes (See ANSI/AAMI ST79, *Comprehensive guide to steam sterilization and sterility assurance in health care facilities*; ANSI/AAMI ST58, *Chemical sterilization and high-level disinfection in health care facilities*; and ANSI/AAMI ST41, *Ethylene oxide sterilization in health care facilities: Safety and effectiveness*).
- b) Specific construction and performance criteria for steam sterilizers (see ANSI/AAMI ST8, *Hospital steam sterilizers* and ANSI/AAMI ST55, *Table-top steam sterilizers*), ethylene oxide gas sterilizers (see ANSI/AAMI ST24, *Automatic, general-purpose ethylene oxide sterilizers and ethylene oxide sterilant sources intended for use in health care facilities*), rigid sterilization container systems (see ANSI/AAMI ST77, *Containment devices for reusable medical device sterilization*), or rigid, protective organizing cases that require wrapping before sterilization (see ANSI/AAMI ST77).
- c) The use of containment devices for packaging items other than instrument sets or procedural trays.
- d) The processing of devices labeled for single use only (see Food and Drug Administration [FDA], 2000c).

NOTE—For more information on the subjects excluded from the scope of this recommended practice, and for additional background information on the inclusions, refer to the references listed in the bibliography.

2 Definitions and abbreviations

2.1 Automated endoscope reprocessor (AER): AERs or endoscope washer-disinfectors are machines designed for the purpose of cleaning and/or disinfecting endoscopes and components. The disinfection process uses a liquid chemical sterilant (LCS) or high-level disinfectant (HLD) solution to achieve at a minimum high-level disinfection.

2.2 bioburden: Population of viable microorganisms on a product and/or a sterile barrier system.

NOTE—When measured, bioburden is expressed as the total count of bacterial and fungal colony-forming units (CFUs) per single item.

2.3 biofilm: Accumulated biomass of bacteria and extracellular material that is tightly adhered to a surface and cannot be removed easily (Donlan, 2002).